Drug safety under scrutiny in major lung cancer survey
NCT ID NCT05100069
Summary
This study is monitoring the safety of Brigatinib tablets in 500 Japanese patients with advanced non-small cell lung cancer. Participants will take the drug as part of their standard care for one year. The main goal is to track side effects, with a special focus on lung-related complications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda Selected Site
RECRUITINGTokyo, Japan
Conditions
Explore the condition pages connected to this study.